Adrenogenital Syndrome Treatment Market Report 2026

The adrenogenital syndrome treatment market size has grown strongly in recent years. It will grow from $12.8 billion in 2025 to $13.56 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to limited availability of synthetic corticosteroids, increasing awareness of adrenogenital syndrome, growth of hospital and clinic infrastructure, rising prevalence of congenital adrenal hyperplasia, adoption of oral and parenteral administration routes.

The adrenogenital syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $16.95 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to advancement in genetic testing technologies, rising demand for personalized hormone therapies, growth in home care treatment adoption, development of new corticosteroid formulations, expansion of hospital and retail pharmacy networks. Major trends in the forecast period include increasing adoption of hormone replacement therapies, rising use of genetic testing for early diagnosis, expansion of mineralocorticoid and glucocorticoid treatments, growing home care and personalized treatment options, enhanced focus on patient monitoring and safety.

The increasing adoption of personalized medicines is expected to drive the growth of the adrenogenital syndrome treatment market going forward. Personalized medicines are therapies tailored to an individual’s genetic profile, lifestyle, and health requirements to enhance efficacy and safety. The rising adoption of personalized medicine is fueled by advances in genetics, growing patient demand for customized treatments, and improvements in healthcare technologies. Personalized treatments for adrenogenital syndrome adjust therapy based on an individual’s specific genetic profile and hormone levels, optimizing outcomes while minimizing side effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that FDA approvals for personalized therapies increased to 16 in 2023, including seven for cancer and three for other conditions, up from six in 2022. Therefore, the rising adoption of personalized medicines is driving the growth of the adrenogenital syndrome treatment market.

Major companies operating in the adrenogenital syndrome treatment market are focused on developing advanced therapies, such as innovative orphan drugs, to address unmet medical needs, improve patient outcomes, and expand their market presence by providing targeted treatments for rare and complex disorders. Orphan drugs are medicines developed for rare, often severe diseases affecting a small patient population, where few or no treatment options exist. For instance, in December 2024, Neurocrine Biosciences, a US-based biotechnology company, announced that it had received FDA approval for CRENESSITY (crinecerfont), an innovative therapy for children and adults with classic Congenital Adrenal Hyperplasia (CAH), a type of adrenogenital syndrome. This approval represents a major milestone, introducing the first new treatment for CAH in seventy years and addressing a critical gap in care for this rare endocrine disorder.

In January 2023, Kaken Pharmaceutical, a Japan-based provider of specialty pharmaceuticals across dermatology, orthopedics, and rare disease therapeutics, partnered with Spruce Biosciences to advance innovative therapies for patients with rare endocrine disorders. The collaboration aims to expand Kaken’s rare endocrine disorder portfolio and accelerate the development of Spruce Biosciences’ CRF1-antagonist therapy, tildacerfont, for congenital adrenal hyperplasia (CAH). Spruce Biosciences is a US-based biopharmaceutical company developing a treatment for congenital adrenal hyperplasia (CAH), which is associated with adrenogenital syndrome.

Major companies operating in the adrenogenital syndrome treatment market are Pfizer Inc, Novartis AG, Sanofi SA, Merck KGaA, Bayer AG, GlaxoSmithKline plc, AstraZeneca plc, Eli Lilly and Company, AbbVie Inc, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd, Viatris Inc, Sun Pharmaceutical Industries Limited, Dr Reddy’s Laboratories Ltd, Cipla Limited, Lupin Limited, Aurobindo Pharma Limited, Zydus Lifesciences Limited, Hikma Pharmaceuticals plc, Amneal Pharmaceuticals Inc, Endo International plc, Alkermes plc, Neurocrine Biosciences Inc.

North America was the largest region in the adrenogenital syndrome treatment market in 2025. The regions covered in the adrenogenital syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adrenogenital syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the adrenogenital syndrome treatment market by increasing the cost of imported corticosteroids, genetic testing kits, and surgical equipment. Segments such as glucocorticoids, mineralocorticoids, and hormone replacement therapies are most affected, with north america, europe, and asia-pacific regions facing higher import duties. This has resulted in increased treatment costs and supply chain challenges. On the positive side, tariffs have encouraged local manufacturing of therapies and kits, promoting regional self-sufficiency and innovation in treatment options.

The adrenogenital syndrome treatment market research report is one of a series of new reports that provides adrenogenital syndrome treatment market statistics, including adrenogenital syndrome treatment industry global market size, regional shares, competitors with a adrenogenital syndrome treatment market share, detailed adrenogenital syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the adrenogenital syndrome treatment industry. This adrenogenital syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Adrenogenital syndrome is a genetic disorder that affects the adrenal glands, causing an imbalance in hormone production, particularly cortisol and aldosterone. Treatment aims to restore hormonal balance using corticosteroids to manage symptoms and prevent complications such as adrenal crises and abnormal growth patterns.

The main drug types for adrenogenital syndrome treatment are mineralocorticoids and glucocorticoids. Mineralocorticoids are a class of steroid hormones that regulate mineral balance, especially sodium and potassium, with aldosterone being the most recognized example. These drugs are administered via various routes, including oral, parenteral, intravenous, and inhalation, and involve key technologies such as genetic testing, hormone replacement therapies, and surgical procedures. They are distributed through hospital and retail pharmacies and are used in hospitals, clinics, and home care settings.

The adrenogenital syndrome treatment market consists of revenues earned by entities by providing services such as therapy services, psychological and psychosocial support services, telemedicine, and remote monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The adrenogenital syndrome treatment market also includes sales of androgen modulators, dietary and nutritional supplements, and diagnostic and monitoring tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.